Sign In
Buy SYRE
$73.52
+4.36 (+6.30%)
At Close: Jun 03, 2026
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
08:00am, Wednesday, 03'rd Jun 2026
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
04:10pm, Tuesday, 26'th May 2026
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Tuesday, 05'th May 2026
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Ann
Spyre Therapeutics Announces Grants of Inducement Awards
04:28pm, Friday, 01'st May 2026
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies an
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
01:36pm, Thursday, 23'rd Apr 2026
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade
02:19am, Wednesday, 15'th Apr 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s share price gapped up before the market opened on Tuesday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
10:38pm, Tuesday, 14'th Apr 2026
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody e
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
07:45am, Tuesday, 14'th Apr 2026
Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical remi
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
04:46pm, Monday, 13'th Apr 2026
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody e
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug
01:29pm, Monday, 13'th Apr 2026
• Spyre Therapeutics stock is approaching key resistance levels. Why is SYRE stock breaking out?
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefi
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears
06:58am, Wednesday, 08'th Apr 2026
The CEO of Spyre Therapeutics reported selling 15,000 shares for a total transaction value of about $740,000 on April 1, 2026. The transaction represented 2.33% of Cameron Turtle's directly held commo
